Michelangelo Fiorentino

[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial.

Zanoni L, Bianchi L, Nanni C, Pultrone C, Giunchi F, Bossert I, Matti A, Schiavina R, Fiorentino M, Romagnoli D, Fonti C, Lodi F, D'Errico A, Brunocilla E, Porreca A, Fanti S.

Eur J Nucl Med Mol Imaging. 2021 Jul 02. PMID: 34213609

Giant (pseudo) vascular spiradenoma: a case report of an extremely rare entity with the immunohistological demonstration of the coexistence of vascular and pseudo-vascular components.

Ricci C, Ambrosi F, Dika E, Lambertini M, Chillotti S, Fiorentino M, Corti B.

Ital J Dermatol Venerol. 2021 Apr 23. PMID: 33890732

Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.

Rizzo A, Mollica V, Rosellini M, Marchetti A, Ricci AD, Fiorentino M, Battelli N, Santoni M, Massari F.

Pathol Res Pract. 2021 Jun. 222:153440. PMID: 33857854

The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis.

Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone CV, Nanni C, Bossert I, Matti A, Schiavina R, Fiorentino M, Fonti C, Lodi F, D'Errico A, Brunocilla E, Fanti S.

Cancers (Basel). 2021 Mar 29. 13(7). PMID: 33805543

Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance.

Borghesi M, Bianchi L, Barbaresi U, Vagnoni V, Corcioni B, Gaudiano C, Fiorentino M, Giunchi F, Chessa F, Garofalo M, Bertaccini A, Angelini S, Ercolino A, Casablanca C, Droghetti M, Golfieri R, Schiavina R.

Minerva Urol Nephrol. 2021 Jun. 73(3):357-366. PMID: 33769008

Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.

Rizzo A, Mollica V, Giunchi F, Dall'Olio FG, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, Fiorentino M, Ardizzoni A, Massari F.

Pathol Res Pract. 2021 Apr. 220:153410. PMID: 33765474

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.

Dall'Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, Fontana F, Terracciano M, Fragomeno B, Tober N, Manferrari G, Brocchi S, Golfieri R, Fiorentino M, Ardizzoni A.

Clin Lung Cancer. 2021 Mar 16. PMID: 33849808

A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?

Giunchi F, Franceschini T, Fiorentino M.

Transl Androl Urol. 2021 Mar. 10(3):1553-1561. PMID: 33850789

Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer.

Zelic R, Giunchi F, Lianas L, Mascia C, Zanetti G, Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Molinaro L, Vincent PH, Richiardi L, Akre O, Fiorentino M, Pettersson A.

Sci Rep. 2021 Feb 05. 11(1):3257. PMID: 33547336

Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing.

Mollica V, Franceschini T, Gruppioni E, Rizzo A, Ricci C, Schiavina R, Brunocilla E, Ardizzoni A, Fiorentino M, Giunchi F, Massari F.

Pathol Res Pract. 2021 Mar. 219:153350. PMID: 33556910